The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: A study of 20 cases

American Journal of Surgical Pathology

Volumn 30, Issue 1, 2006, Pages 1-6

  Winstanley, Alison M ^a,d   Landon, Giorgio ^a   Berney, Dan ^b   Minhas, Suks ^a   Fisher, Cyril ^c   Parkinson, Margaret C ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Immunohistochemistry; Mesothelioma; Paratestis; Testis; Tunica vaginalis

Indexed keywords

ASBESTOS; CALRETININ; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; EPITHELIAL MEMBRANE ANTIGEN; PROTEIN BEREP4; THROMBOMODULIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; MICROVILLUS; ORCHIECTOMY; PLEURA MESOTHELIOMA; TESTIS CANCER; TUNICA VAGINALIS; MESOTHELIOMA; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TESTIS TUMOR; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

AGED; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 31544443084     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000178094.07513.71     Document Type: Article

References (39)

1. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55:662-668.
2. Agapitos E, Pavlopoulos PM, Marinos E, et al. Malignant mesothelioma of the tunica vaginalis testis: an immunohistochemical and ultrastructural study of two cases. Br J Urol. 1997;80:345-346.
3. Amin MB. Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumours, mesothelial lesions and secondary tumours. Mod Pathol. 2005;18(suppl 2):131-145.
4. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology. 1996;29:209-215.
5. Attanoos RL, Gibbs AR. Primary gonadal mesotheliomas and asbestos. Histopathology. 2000;37:150-159.
6. Attanoos RL, Webb R, Dojcinov SD, et al. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology. 2001;39:584-588.
7. Bailey GN, Willis RA, Wilson JV. A case of adenocarcinoma of the appendix testis. J Pathol Bacteriol. 1955;69:326.
8. Berti E, Schiaffino E, Minervini MS, et al. Primary malignant mesothelioma of the tunica vaginalis of the testis: immunohistochemistry and electron microscopy. Pathology. 1997;29:96-99.
9. Bostwick DG. Spermatic cord and testicular adenexa. In: Bostwick DG, Eble JN, eds. Urologic Surgical Pathology. St. Louis: Mosby, 1997:661.
10. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001;25:43-50.
11. Churg A. Paratesticular mesothelioma proliferations. Semin Diagn Pathol. 2003;20:272-278.
12. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
13. Comin CE, Novelli L, Boddi V et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32:529-536.
14. Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol. 1982;108:80-87.
15. Cury PM, Butcher DN, Fisher C, et al. Value of mesothelium-associated antibodies thrombomodulin, cytokeratins 5/6, calretinin and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13:107-112.
16. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189:251-257.
17. Dejmek A. Methods to improve the diagnostic accuracy of malignant mesothelioma. Respir Med. 1996;90:191-199.
18. Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
19. Eimoto T, Inoue I. Malignant fibrous mesothelioma of the tunica vaginalis. Cancer. 1977;39:2059-2066.
20. Gaffey MJ, Mills SE, Swanson PE, et al. Immunoreactivity for Ber-Ep4 in adenocarcinomas, adenomatoid tumours and malignant mesotheliomas. Am J Surg Pathol. 1992;16:593-599.
21. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract. 1996;192:137-147.
22. Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol. 1984;8:277-279.
23. Jones MA, Young RH, Scully RE. Malignant mesothelioma of the tunica vaginalis: a clinicopathological analysis of 11 cases with review of the literature. Am J Surg Pathol. 1995;19:815-825.
24. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of the pleura. J Clin Pathol. 1997;50:859-862.
25. King JA, Tucker JA. Evaluation of membranous staining of mesothelioma. Cell Vis. 1998;5:24-27.
26. Mikuz G, Hopfel-Kreiner I. Papillary mesothelioma of the tunica vaginalis propria testis: case report and ultrastructural study. Virchows Arch A Pathol Anat Histol. 1982;396:231-238.
27. Ordonez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology. 1997;31:25-30.
28. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol. 1998;11: 929-933.
29. Ordonez NG. Value of the Ber-Ep4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma: the M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol. 1998;109:85-89.
30. Perez-Ordonez B, Srigley JR, Thomas MJ, et al. Malignant mesothelioma of the tunica vaginalis a clinicopathological study of 13 cases. Arch Anat Cytol Path Clin Exp Path. 1998;46:430.
31. Perez-Ordonez B, Srigley JR. Mesothelial lesions of the paratesticular region. Semin Diagn Pathol. 2000;17:294-306.
32. Pizzolato P, Lamberty J. Mesothelioma of the spermatic cord: electron microscopic and histochemical characteristics of its mucopolysaccharides. Urology. 1976;8:403-408.
33. Plas E, Riedl CR, Pfluger H. Malignant mesothelioma of the tunica vaginalis testis: review of literature and assessment of prognostic parameters. Cancer. 1998;83:2437-2446.
34. Robb JA. Mesothelioma versus adenocarcinoma: false positive CEA and Leu-M1 staining due to hylauronic acid [Letter]. Hum Pathol. 1989;20:400.
35. Sheibani K, Shin SS, Kezirian J, et al. Ber-Ep4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol. 1991;15:779-784.
36. Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer. 2001;92:2727-2732.
37. Ulbright TM. Neoplasms of the testis. In: Bostwick DG, Eble JN, eds. Urologic Surgical Pathology. St Louis: Mosby, 1997:630-631.
38. Wiedorn KH, Goldmann T, Henne C, et al. EnVision+, a new dextran polymer-based signal enhancement technique for in situ hybridization. J Histochem Cytochem. 2001;49:1067-1071.
39. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer. 1998;82:583-590.